Antibody-drug conjugate · Cytotoxic, directed at ADAM9 · developed by MacroGenics
MGC028 is an antibody-drug conjugate in which a humanized anti-ADAM9 antibody is linked to the topoisomerase I inhibitor exatecan through a cleavable linker. The antibody binds ADAM9 on tumor cells, and after internalization the released exatecan inhibits DNA topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in advanced solid tumors, non-small cell lung cancer adenocarcinoma, cholangiocarcinoma, pancreatic carcinoma and colorectal carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06723236 | Phase 1 | Advanced Solid Tumors | Recruiting | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsCholangiocarcinomaColorectal CarcinomaNSCLC AdenocarcinomaPancreatic Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →